Type I interferons in anticancer immunity View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-06-01

AUTHORS

Laurence Zitvogel, Lorenzo Galluzzi, Oliver Kepp, Mark J. Smyth, Guido Kroemer

ABSTRACT

Key PointsThe type I interferon (IFN) system involves a single form of IFNβ, several variants of IFNα and other less well-characterized IFNs, all of which signal via a heterodimeric IFNα/β receptor 1 (IFNAR1)–IFNAR2 receptor to transactivate IFN-stimulated genes (ISGs). IFNβ also promotes the transactivation of ISGs through homodimeric IFNAR1.The secretion of type I IFNs is stimulated by viral constituents, as well as by danger signals emitted by dying cells, including nuclear and mitochondrial nucleic acids found at ectopic locations. The production of type I IFNs has marked antiviral and immunostimulatory effects.Beyond their role in curtailing viral infection, type I IFNs play an essential part in natural cancer immunosurveillance, functioning both at the level of malignant cell precursors and through effects on the immune system. Thus, the knockout of Ifnar1 in mouse epithelial cells predisposes them to malignant transformation, as does the knockout of Ifnar1 in leukocytes, especially dendritic cells.Type I IFN signalling is also essential for the full-blown efficacy of various anticancer agents, including chemotherapeutics (such as anthracyclines), antibodies that target growth factor receptors (such as human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR)), the injection of adjuvants and oncolytic virotherapy.The expression levels of ISGs constitute a positive prognostic or predictive biomarker in patients affected by several cancers including melanoma and breast carcinoma. Recombinant type I IFNs have been successfully used for the treatment of various human neoplasms, particularly ulcerative melanoma, renal cell carcinoma and hepatitis B virus (HBV)-induced hepatocellular carcinoma.Preclinical data identify four distinct approaches to improve the targeted delivery of type I IFNs to malignant lesions: first, fusing or linking recombinant type I IFNs to antibodies specific for tumour-associated surface antigens; second, engineering leukocytes or mesenchymal stem cells to express type I IFNs once they have infiltrated neoplastic lesions; third, injecting type I IFN-encoding vectors into the tumour mass; and fourth, supplying artificial ligands of type I IFN-stimulating pattern recognition receptors (PRRs). More... »

PAGES

405-414

References to SciGraph publications

  • 2012-12-14. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia in LEUKEMIA
  • 2015-01-23. Type I interferons in infectious disease in NATURE REVIEWS IMMUNOLOGY
  • 2013-07-21. Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1 in NATURE IMMUNOLOGY
  • 2012-07-22. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape in NATURE MEDICINE
  • 2010-04-20. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors in NATURE IMMUNOLOGY
  • 2013-09-18. Innate and adaptive immune cells in the tumor microenvironment in NATURE IMMUNOLOGY
  • 2002-09. Viruses and interferon: a fight for supremacy in NATURE REVIEWS IMMUNOLOGY
  • 2013-06-13. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function in GENE THERAPY
  • 2012-03-22. The blockade of immune checkpoints in cancer immunotherapy in NATURE REVIEWS CANCER
  • 2013-08-20. IFN-β-specific signaling via a unique IFNAR1 interaction in NATURE IMMUNOLOGY
  • 2012-06-22. Innate immune sensing of cancer: clues from an identified role for type I IFNs in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2013-11-04. Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo in ONCOGENE
  • 2012-11-23. Mitochondria: master regulators of danger signalling in NATURE REVIEWS MOLECULAR CELL BIOLOGY
  • 2013-09-13. Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα+ tumorigenesis in CELL DEATH & DIFFERENTIATION
  • 2005. Interferons in the Treatment of Solid Tumors in CYTOKINES AND CANCER
  • 2014-10-26. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy in NATURE MEDICINE
  • 2007-11-18. Adaptive immunity maintains occult cancer in an equilibrium state in NATURE
  • 2014-01-08. High efficiency cell-specific targeting of cytokine activity in NATURE COMMUNICATIONS
  • 2013-11-14. Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years’ experience in a single centre in ANNALS OF HEMATOLOGY
  • 2008-11-02. 5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma in NATURE MEDICINE
  • 2011-09-25. STING is a direct innate immune sensor of cyclic di-GMP in NATURE
  • 2005-06-12. A critical function for type I interferons in cancer immunoediting in NATURE IMMUNOLOGY
  • 2009-04-16. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity in NATURE
  • 2014-11-28. Type I IFN gene delivery suppresses regulatory T cells within tumors in CANCER GENE THERAPY
  • Journal

    TITLE

    Nature Reviews Immunology

    ISSUE

    7

    VOLUME

    15

    Related Patents

  • Sting-Dependent Activator For The Treatment Of Diseases
  • Pirin Polypeptide And Immune Modulation
  • Bispecific Signaling Agents And Uses Thereof
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Clec9a Binding Agents And Use Thereof
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compounds
  • Compositions Comprising Bacterial Strains
  • Compounds
  • Compositions Comprising Bacterial Strains
  • Sustained Production Of High Affinity Antigen Specific Antibody By High Dose Baff Receptor-Targeting Mab-Sirna Conjugate
  • Compounds
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compounds
  • Composition Comprising Bacterial Strains
  • Methods And Compositions For Treating Cancer
  • Chimeric Viruses Presenting Non-Native Surface Proteins And Uses Thereof
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Newcastle Disease Viruses And Uses Thereof
  • Bispecific Signaling Agents And Uses Thereof
  • Compositions Comprising Bacterial Strains
  • Targeted Therapeutic Agents And Uses Thereof
  • Bacterium For Use As A Probiotic For Nutritional And Medical Applications
  • Compositions Comprising Bacterial Strains
  • Polypeptide And Immune Modulation
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Cd8 Binding Agents
  • Compositions Comprising Bacterial Strains
  • Fusion Protein Composition(S) Comprising Masked Type I Interferons (Ifna And Ifnb) For Use In The Treatment Of Cancer And Methods Thereof
  • Composition Of Bacteroides Thetaiotaomicron For Immune Modulation
  • Compositions Comprising Bacterial Strains
  • Methods For Predicting The Risk Of Recurrence And/Or Death Of Patients Suffering From A Solid Cancer After Preoperative Adjuvant Therapy And Radical Surgery
  • Compositions Comprising Bacterial Strains
  • Trailshort Antibody And Methods Of Use
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Pirin Polypeptide And Immune Modulation
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Cyclic Di-Nucleotides As Modulators Of Sting
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Engineered Immunostimulatory Bacterial Strains And Uses Thereof
  • Compositions Comprising Bacterial Strains
  • Polypeptide And Immune Modulation
  • Combination Therapy Comprising An Axl Inhibitor
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising A Bacterial Strain Of The Genus Megasphera And Uses Thereof
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Method Of Selecting Patients For Treatment With A Combination Of An Axl Inhibitor And An Immune Checkpoint Modulator
  • Methods For Predicting The Risk Of Recurrence And/Or Death Of Patients Suffering From A Solid Cancer After Preoperative Adjuvant Therapies
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strains
  • Activatable Cytokine Constructs And Related Compositions And Methods
  • Cd8 Binding Agents
  • Compositions Comprising Bacterial Strains
  • Cyclic Dinucleotides Useful For The Treatment Of Inter Alia Cancer
  • Combination Method For Treatment Of Cancer
  • Engineered Immunostimulatory Bacterial Strains And Uses Thereof
  • Compositions Comprising Bacterial Strains
  • Compositions Comprising Bacterial Strain
  • Lactic Acid Bacterial Strains
  • Clec9a Binding Agents
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nri3845

    DOI

    http://dx.doi.org/10.1038/nri3845

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1049369736

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/26027717


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Interferon Type I", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasms", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800, Villejuif, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Gustave Roussy Cancer Campus, F-94800, Villejuif, France", 
                "INSERM, U1015, F-94800, Villejuif, France", 
                "Universit\u00e9 Paris Sud/Paris XI, Facult\u00e9 de M\u00e9decine, F-94270, Le Kremlin Bic\u00eatre, France", 
                "Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800, Villejuif, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zitvogel", 
            "givenName": "Laurence", 
            "id": "sg:person.01214767546.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214767546.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Universit\u00e9 Pierre et Marie Curie/Paris VI, F-75006, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462844.8", 
              "name": [
                "Gustave Roussy Cancer Campus, F-94800, Villejuif, France", 
                "Equipe 11 labellis\u00e9e par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006, Paris, France", 
                "INSERM, U1138, F-75006, Paris, France", 
                "Universit\u00e9 Paris Descartes/Paris V, Sorbonne Paris Cit\u00e9, F-75006, Paris, France", 
                "Universit\u00e9 Pierre et Marie Curie/Paris VI, F-75006, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Galluzzi", 
            "givenName": "Lorenzo", 
            "id": "sg:person.0601212465.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601212465.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800, Villejuif, France", 
              "id": "http://www.grid.ac/institutes/grid.14925.3b", 
              "name": [
                "Equipe 11 labellis\u00e9e par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006, Paris, France", 
                "INSERM, U1138, F-75006, Paris, France", 
                "Universit\u00e9 Paris Descartes/Paris V, Sorbonne Paris Cit\u00e9, F-75006, Paris, France", 
                "Universit\u00e9 Pierre et Marie Curie/Paris VI, F-75006, Paris, France", 
                "Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800, Villejuif, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kepp", 
            "givenName": "Oliver", 
            "id": "sg:person.0744504154.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744504154.14"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "School of Medicine, University of Queensland, 4006, Herston, QLD, Australia", 
              "id": "http://www.grid.ac/institutes/grid.1003.2", 
              "name": [
                "Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, 4006, Herston, QLD, Australia", 
                "School of Medicine, University of Queensland, 4006, Herston, QLD, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Smyth", 
            "givenName": "Mark J.", 
            "id": "sg:person.01010600434.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010600434.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "P\u00f4le de Biologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, F-75015, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.414093.b", 
              "name": [
                "Equipe 11 labellis\u00e9e par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006, Paris, France", 
                "INSERM, U1138, F-75006, Paris, France", 
                "Universit\u00e9 Paris Descartes/Paris V, Sorbonne Paris Cit\u00e9, F-75006, Paris, France", 
                "Universit\u00e9 Pierre et Marie Curie/Paris VI, F-75006, Paris, France", 
                "Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800, Villejuif, France", 
                "P\u00f4le de Biologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, F-75015, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kroemer", 
            "givenName": "Guido", 
            "id": "sg:person.0610375740.57", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610375740.57"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nature07750", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002832330", 
              "https://doi.org/10.1038/nature07750"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.2667", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021834367", 
              "https://doi.org/10.1038/ni.2667"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrm3479", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022835250", 
              "https://doi.org/10.1038/nrm3479"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/cdd.2013.116", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021653597", 
              "https://doi.org/10.1038/cdd.2013.116"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni1213", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024014898", 
              "https://doi.org/10.1038/ni1213"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature10429", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012079432", 
              "https://doi.org/10.1038/nature10429"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc3239", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047946992", 
              "https://doi.org/10.1038/nrc3239"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/0-387-24361-5_9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014568276", 
              "https://doi.org/10.1007/0-387-24361-5_9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/gt.2013.31", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000311326", 
              "https://doi.org/10.1038/gt.2013.31"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.3708", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034226043", 
              "https://doi.org/10.1038/nm.3708"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00277-013-1934-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020569702", 
              "https://doi.org/10.1007/s00277-013-1934-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.2686", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000960688", 
              "https://doi.org/10.1038/ni.2686"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/cgt.2014.60", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042539797", 
              "https://doi.org/10.1038/cgt.2014.60"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms4016", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010138519", 
              "https://doi.org/10.1038/ncomms4016"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.2830", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044584714", 
              "https://doi.org/10.1038/nm.2830"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri3787", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007717765", 
              "https://doi.org/10.1038/nri3787"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.1863", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036256011", 
              "https://doi.org/10.1038/ni.1863"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2013.458", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021782376", 
              "https://doi.org/10.1038/onc.2013.458"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature06309", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000116337", 
              "https://doi.org/10.1038/nature06309"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.2703", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009839834", 
              "https://doi.org/10.1038/ni.2703"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.1887", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030095863", 
              "https://doi.org/10.1038/nm.1887"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2012.313", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028566170", 
              "https://doi.org/10.1038/leu.2012.313"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-012-1305-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049537134", 
              "https://doi.org/10.1007/s00262-012-1305-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri888", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004545980", 
              "https://doi.org/10.1038/nri888"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2015-06-01", 
        "datePublishedReg": "2015-06-01", 
        "description": "Key PointsThe type I interferon (IFN) system involves a single form of IFN\u03b2, several variants of IFN\u03b1 and other less well-characterized IFNs, all of which signal via a heterodimeric IFN\u03b1/\u03b2 receptor 1 (IFNAR1)\u2013IFNAR2 receptor to transactivate IFN-stimulated genes (ISGs). IFN\u03b2 also promotes the transactivation of ISGs through homodimeric IFNAR1.The secretion of type I IFNs is stimulated by viral constituents, as well as by danger signals emitted by dying cells, including nuclear and mitochondrial nucleic acids found at ectopic locations. The production of type I IFNs has marked antiviral and immunostimulatory effects.Beyond their role in curtailing viral infection, type I IFNs play an essential part in natural cancer immunosurveillance, functioning both at the level of malignant cell precursors and through effects on the immune system. Thus, the knockout of Ifnar1 in mouse epithelial cells predisposes them to malignant transformation, as does the knockout of Ifnar1 in leukocytes, especially dendritic cells.Type I IFN signalling is also essential for the full-blown efficacy of various anticancer agents, including chemotherapeutics (such as anthracyclines), antibodies that target growth factor receptors (such as human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR)), the injection of adjuvants and oncolytic virotherapy.The expression levels of ISGs constitute a positive prognostic or predictive biomarker in patients affected by several cancers including melanoma and breast carcinoma. Recombinant type I IFNs have been successfully used for the treatment of various human neoplasms, particularly ulcerative melanoma, renal cell carcinoma and hepatitis B virus (HBV)-induced hepatocellular carcinoma.Preclinical data identify four distinct approaches to improve the targeted delivery of type I IFNs to malignant lesions: first, fusing or linking recombinant type I IFNs to antibodies specific for tumour-associated surface antigens; second, engineering leukocytes or mesenchymal stem cells to express type I IFNs once they have infiltrated neoplastic lesions; third, injecting type I IFN-encoding vectors into the tumour mass; and fourth, supplying artificial ligands of type I IFN-stimulating pattern recognition receptors (PRRs).", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nri3845", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1029717", 
            "issn": [
              "1474-1733", 
              "1474-1741"
            ], 
            "name": "Nature Reviews Immunology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "15"
          }
        ], 
        "keywords": [
          "type I IFN", 
          "recombinant type I IFN", 
          "type I IFNs", 
          "I IFN", 
          "pattern recognition receptors", 
          "I IFNs", 
          "tumor-associated surface antigen", 
          "injection of adjuvant", 
          "type I interferon system", 
          "hepatitis B virus", 
          "renal cell carcinoma", 
          "\u03b2 receptor 1", 
          "type I", 
          "growth factor receptor", 
          "anticancer immunity", 
          "dendritic cells", 
          "cancer immunosurveillance", 
          "cell carcinoma", 
          "predictive biomarkers", 
          "preclinical data", 
          "B virus", 
          "breast carcinoma", 
          "neoplastic lesions", 
          "hepatocellular carcinoma", 
          "oncolytic virotherapy", 
          "tumor mass", 
          "malignant lesions", 
          "immunostimulatory effects", 
          "viral infection", 
          "surface antigen", 
          "IFN", 
          "danger signals", 
          "mesenchymal stem cells", 
          "immune system", 
          "recognition receptors", 
          "receptor 1", 
          "malignant transformation", 
          "human neoplasms", 
          "interferon system", 
          "ectopic locations", 
          "carcinoma", 
          "cell precursors", 
          "factor receptor", 
          "epithelial cells", 
          "mouse epithelial cells", 
          "viral constituents", 
          "receptors", 
          "expression levels", 
          "IFN\u03b2", 
          "anticancer agents", 
          "melanoma", 
          "lesions", 
          "leukocytes", 
          "IFNs", 
          "stem cells", 
          "mitochondrial nucleic acids", 
          "antibodies", 
          "IFNAR1", 
          "cells", 
          "ISGs", 
          "knockout", 
          "IFNAR2 receptor", 
          "patients", 
          "immunosurveillance", 
          "IFN\u03b1", 
          "neoplasms", 
          "adjuvant", 
          "virotherapy", 
          "infection", 
          "cancer", 
          "antigen", 
          "artificial ligands", 
          "immunity", 
          "secretion", 
          "biomarkers", 
          "efficacy", 
          "virus", 
          "levels", 
          "treatment", 
          "nucleic acids", 
          "injection", 
          "chemotherapeutics", 
          "delivery", 
          "effect", 
          "transactivation", 
          "agents", 
          "genes", 
          "single form", 
          "variants", 
          "role", 
          "essential part", 
          "acid", 
          "mass", 
          "data", 
          "constituents", 
          "production", 
          "ligands", 
          "vector", 
          "precursors", 
          "part", 
          "location", 
          "system", 
          "form", 
          "signals", 
          "distinct approaches", 
          "approach", 
          "transformation"
        ], 
        "name": "Type I interferons in anticancer immunity", 
        "pagination": "405-414", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1049369736"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nri3845"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "26027717"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nri3845", 
          "https://app.dimensions.ai/details/publication/pub.1049369736"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:32", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_649.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nri3845"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nri3845'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nri3845'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nri3845'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nri3845'


     

    This table displays all metadata directly associated to this object as RDF triples.

    345 TRIPLES      21 PREDICATES      162 URIs      129 LITERALS      12 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nri3845 schema:about N49a6dbfb90c745b2b5637ee0190ab0ab
    2 N4e05e2f90a4d4b208d89b69e19828f67
    3 N90e5f019753540dba0f466d5c2362af5
    4 Na3cd6ca785614a76b5786ff4b6da1f4d
    5 Na44ed488c94b4f3ba911132373240900
    6 anzsrc-for:11
    7 anzsrc-for:1107
    8 anzsrc-for:1112
    9 schema:author Ne6be99af04ae430b8e7431dd9c268751
    10 schema:citation sg:pub.10.1007/0-387-24361-5_9
    11 sg:pub.10.1007/s00262-012-1305-6
    12 sg:pub.10.1007/s00277-013-1934-7
    13 sg:pub.10.1038/cdd.2013.116
    14 sg:pub.10.1038/cgt.2014.60
    15 sg:pub.10.1038/gt.2013.31
    16 sg:pub.10.1038/leu.2012.313
    17 sg:pub.10.1038/nature06309
    18 sg:pub.10.1038/nature07750
    19 sg:pub.10.1038/nature10429
    20 sg:pub.10.1038/ncomms4016
    21 sg:pub.10.1038/ni.1863
    22 sg:pub.10.1038/ni.2667
    23 sg:pub.10.1038/ni.2686
    24 sg:pub.10.1038/ni.2703
    25 sg:pub.10.1038/ni1213
    26 sg:pub.10.1038/nm.1887
    27 sg:pub.10.1038/nm.2830
    28 sg:pub.10.1038/nm.3708
    29 sg:pub.10.1038/nrc3239
    30 sg:pub.10.1038/nri3787
    31 sg:pub.10.1038/nri888
    32 sg:pub.10.1038/nrm3479
    33 sg:pub.10.1038/onc.2013.458
    34 schema:datePublished 2015-06-01
    35 schema:datePublishedReg 2015-06-01
    36 schema:description Key PointsThe type I interferon (IFN) system involves a single form of IFNβ, several variants of IFNα and other less well-characterized IFNs, all of which signal via a heterodimeric IFNα/β receptor 1 (IFNAR1)–IFNAR2 receptor to transactivate IFN-stimulated genes (ISGs). IFNβ also promotes the transactivation of ISGs through homodimeric IFNAR1.The secretion of type I IFNs is stimulated by viral constituents, as well as by danger signals emitted by dying cells, including nuclear and mitochondrial nucleic acids found at ectopic locations. The production of type I IFNs has marked antiviral and immunostimulatory effects.Beyond their role in curtailing viral infection, type I IFNs play an essential part in natural cancer immunosurveillance, functioning both at the level of malignant cell precursors and through effects on the immune system. Thus, the knockout of Ifnar1 in mouse epithelial cells predisposes them to malignant transformation, as does the knockout of Ifnar1 in leukocytes, especially dendritic cells.Type I IFN signalling is also essential for the full-blown efficacy of various anticancer agents, including chemotherapeutics (such as anthracyclines), antibodies that target growth factor receptors (such as human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR)), the injection of adjuvants and oncolytic virotherapy.The expression levels of ISGs constitute a positive prognostic or predictive biomarker in patients affected by several cancers including melanoma and breast carcinoma. Recombinant type I IFNs have been successfully used for the treatment of various human neoplasms, particularly ulcerative melanoma, renal cell carcinoma and hepatitis B virus (HBV)-induced hepatocellular carcinoma.Preclinical data identify four distinct approaches to improve the targeted delivery of type I IFNs to malignant lesions: first, fusing or linking recombinant type I IFNs to antibodies specific for tumour-associated surface antigens; second, engineering leukocytes or mesenchymal stem cells to express type I IFNs once they have infiltrated neoplastic lesions; third, injecting type I IFN-encoding vectors into the tumour mass; and fourth, supplying artificial ligands of type I IFN-stimulating pattern recognition receptors (PRRs).
    37 schema:genre article
    38 schema:isAccessibleForFree false
    39 schema:isPartOf N10b880ed4c3442dfada4b668cd825301
    40 Nf7655b9cd1414cb3b84c2d6657e01c6f
    41 sg:journal.1029717
    42 schema:keywords B virus
    43 I IFN
    44 I IFNs
    45 IFN
    46 IFNAR1
    47 IFNAR2 receptor
    48 IFNs
    49 IFNα
    50 IFNβ
    51 ISGs
    52 acid
    53 adjuvant
    54 agents
    55 antibodies
    56 anticancer agents
    57 anticancer immunity
    58 antigen
    59 approach
    60 artificial ligands
    61 biomarkers
    62 breast carcinoma
    63 cancer
    64 cancer immunosurveillance
    65 carcinoma
    66 cell carcinoma
    67 cell precursors
    68 cells
    69 chemotherapeutics
    70 constituents
    71 danger signals
    72 data
    73 delivery
    74 dendritic cells
    75 distinct approaches
    76 ectopic locations
    77 effect
    78 efficacy
    79 epithelial cells
    80 essential part
    81 expression levels
    82 factor receptor
    83 form
    84 genes
    85 growth factor receptor
    86 hepatitis B virus
    87 hepatocellular carcinoma
    88 human neoplasms
    89 immune system
    90 immunity
    91 immunostimulatory effects
    92 immunosurveillance
    93 infection
    94 injection
    95 injection of adjuvant
    96 interferon system
    97 knockout
    98 lesions
    99 leukocytes
    100 levels
    101 ligands
    102 location
    103 malignant lesions
    104 malignant transformation
    105 mass
    106 melanoma
    107 mesenchymal stem cells
    108 mitochondrial nucleic acids
    109 mouse epithelial cells
    110 neoplasms
    111 neoplastic lesions
    112 nucleic acids
    113 oncolytic virotherapy
    114 part
    115 patients
    116 pattern recognition receptors
    117 preclinical data
    118 precursors
    119 predictive biomarkers
    120 production
    121 receptor 1
    122 receptors
    123 recognition receptors
    124 recombinant type I IFN
    125 renal cell carcinoma
    126 role
    127 secretion
    128 signals
    129 single form
    130 stem cells
    131 surface antigen
    132 system
    133 transactivation
    134 transformation
    135 treatment
    136 tumor mass
    137 tumor-associated surface antigen
    138 type I
    139 type I IFN
    140 type I IFNs
    141 type I interferon system
    142 variants
    143 vector
    144 viral constituents
    145 viral infection
    146 virotherapy
    147 virus
    148 β receptor 1
    149 schema:name Type I interferons in anticancer immunity
    150 schema:pagination 405-414
    151 schema:productId N5196af1f2a69465490410d2d7929fdad
    152 Na3a9c1c7b753453bbd8058a4c439ea72
    153 Ne6d2f47816c7461cb7b8d4054a9a290f
    154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049369736
    155 https://doi.org/10.1038/nri3845
    156 schema:sdDatePublished 2022-12-01T06:32
    157 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    158 schema:sdPublisher Ncb2322d33fc34d348bdb0f85c2b7adb3
    159 schema:url https://doi.org/10.1038/nri3845
    160 sgo:license sg:explorer/license/
    161 sgo:sdDataset articles
    162 rdf:type schema:ScholarlyArticle
    163 N10b880ed4c3442dfada4b668cd825301 schema:issueNumber 7
    164 rdf:type schema:PublicationIssue
    165 N49a6dbfb90c745b2b5637ee0190ab0ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Immunotherapy
    167 rdf:type schema:DefinedTerm
    168 N4e05e2f90a4d4b208d89b69e19828f67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Neoplasms
    170 rdf:type schema:DefinedTerm
    171 N5196af1f2a69465490410d2d7929fdad schema:name doi
    172 schema:value 10.1038/nri3845
    173 rdf:type schema:PropertyValue
    174 N53c77480460c464bb783f69cc4446b4e rdf:first sg:person.0601212465.19
    175 rdf:rest N97f1f60dba6f40dfbc3067abef9e4704
    176 N90e5f019753540dba0f466d5c2362af5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Animals
    178 rdf:type schema:DefinedTerm
    179 N97f1f60dba6f40dfbc3067abef9e4704 rdf:first sg:person.0744504154.14
    180 rdf:rest Naf00edbf11aa4519b9ededbf02056378
    181 Na3a9c1c7b753453bbd8058a4c439ea72 schema:name dimensions_id
    182 schema:value pub.1049369736
    183 rdf:type schema:PropertyValue
    184 Na3cd6ca785614a76b5786ff4b6da1f4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Interferon Type I
    186 rdf:type schema:DefinedTerm
    187 Na44ed488c94b4f3ba911132373240900 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Humans
    189 rdf:type schema:DefinedTerm
    190 Naf00edbf11aa4519b9ededbf02056378 rdf:first sg:person.01010600434.98
    191 rdf:rest Nc44f693d5ba24e8fabfcacfa4610a1ce
    192 Nc44f693d5ba24e8fabfcacfa4610a1ce rdf:first sg:person.0610375740.57
    193 rdf:rest rdf:nil
    194 Ncb2322d33fc34d348bdb0f85c2b7adb3 schema:name Springer Nature - SN SciGraph project
    195 rdf:type schema:Organization
    196 Ne6be99af04ae430b8e7431dd9c268751 rdf:first sg:person.01214767546.51
    197 rdf:rest N53c77480460c464bb783f69cc4446b4e
    198 Ne6d2f47816c7461cb7b8d4054a9a290f schema:name pubmed_id
    199 schema:value 26027717
    200 rdf:type schema:PropertyValue
    201 Nf7655b9cd1414cb3b84c2d6657e01c6f schema:volumeNumber 15
    202 rdf:type schema:PublicationVolume
    203 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    204 schema:name Medical and Health Sciences
    205 rdf:type schema:DefinedTerm
    206 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    207 schema:name Immunology
    208 rdf:type schema:DefinedTerm
    209 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    210 schema:name Oncology and Carcinogenesis
    211 rdf:type schema:DefinedTerm
    212 sg:journal.1029717 schema:issn 1474-1733
    213 1474-1741
    214 schema:name Nature Reviews Immunology
    215 schema:publisher Springer Nature
    216 rdf:type schema:Periodical
    217 sg:person.01010600434.98 schema:affiliation grid-institutes:grid.1003.2
    218 schema:familyName Smyth
    219 schema:givenName Mark J.
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010600434.98
    221 rdf:type schema:Person
    222 sg:person.01214767546.51 schema:affiliation grid-institutes:None
    223 schema:familyName Zitvogel
    224 schema:givenName Laurence
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214767546.51
    226 rdf:type schema:Person
    227 sg:person.0601212465.19 schema:affiliation grid-institutes:grid.462844.8
    228 schema:familyName Galluzzi
    229 schema:givenName Lorenzo
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601212465.19
    231 rdf:type schema:Person
    232 sg:person.0610375740.57 schema:affiliation grid-institutes:grid.414093.b
    233 schema:familyName Kroemer
    234 schema:givenName Guido
    235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610375740.57
    236 rdf:type schema:Person
    237 sg:person.0744504154.14 schema:affiliation grid-institutes:grid.14925.3b
    238 schema:familyName Kepp
    239 schema:givenName Oliver
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744504154.14
    241 rdf:type schema:Person
    242 sg:pub.10.1007/0-387-24361-5_9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014568276
    243 https://doi.org/10.1007/0-387-24361-5_9
    244 rdf:type schema:CreativeWork
    245 sg:pub.10.1007/s00262-012-1305-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049537134
    246 https://doi.org/10.1007/s00262-012-1305-6
    247 rdf:type schema:CreativeWork
    248 sg:pub.10.1007/s00277-013-1934-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020569702
    249 https://doi.org/10.1007/s00277-013-1934-7
    250 rdf:type schema:CreativeWork
    251 sg:pub.10.1038/cdd.2013.116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021653597
    252 https://doi.org/10.1038/cdd.2013.116
    253 rdf:type schema:CreativeWork
    254 sg:pub.10.1038/cgt.2014.60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042539797
    255 https://doi.org/10.1038/cgt.2014.60
    256 rdf:type schema:CreativeWork
    257 sg:pub.10.1038/gt.2013.31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000311326
    258 https://doi.org/10.1038/gt.2013.31
    259 rdf:type schema:CreativeWork
    260 sg:pub.10.1038/leu.2012.313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028566170
    261 https://doi.org/10.1038/leu.2012.313
    262 rdf:type schema:CreativeWork
    263 sg:pub.10.1038/nature06309 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000116337
    264 https://doi.org/10.1038/nature06309
    265 rdf:type schema:CreativeWork
    266 sg:pub.10.1038/nature07750 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002832330
    267 https://doi.org/10.1038/nature07750
    268 rdf:type schema:CreativeWork
    269 sg:pub.10.1038/nature10429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012079432
    270 https://doi.org/10.1038/nature10429
    271 rdf:type schema:CreativeWork
    272 sg:pub.10.1038/ncomms4016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010138519
    273 https://doi.org/10.1038/ncomms4016
    274 rdf:type schema:CreativeWork
    275 sg:pub.10.1038/ni.1863 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036256011
    276 https://doi.org/10.1038/ni.1863
    277 rdf:type schema:CreativeWork
    278 sg:pub.10.1038/ni.2667 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021834367
    279 https://doi.org/10.1038/ni.2667
    280 rdf:type schema:CreativeWork
    281 sg:pub.10.1038/ni.2686 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000960688
    282 https://doi.org/10.1038/ni.2686
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.1038/ni.2703 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009839834
    285 https://doi.org/10.1038/ni.2703
    286 rdf:type schema:CreativeWork
    287 sg:pub.10.1038/ni1213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024014898
    288 https://doi.org/10.1038/ni1213
    289 rdf:type schema:CreativeWork
    290 sg:pub.10.1038/nm.1887 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030095863
    291 https://doi.org/10.1038/nm.1887
    292 rdf:type schema:CreativeWork
    293 sg:pub.10.1038/nm.2830 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044584714
    294 https://doi.org/10.1038/nm.2830
    295 rdf:type schema:CreativeWork
    296 sg:pub.10.1038/nm.3708 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034226043
    297 https://doi.org/10.1038/nm.3708
    298 rdf:type schema:CreativeWork
    299 sg:pub.10.1038/nrc3239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047946992
    300 https://doi.org/10.1038/nrc3239
    301 rdf:type schema:CreativeWork
    302 sg:pub.10.1038/nri3787 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007717765
    303 https://doi.org/10.1038/nri3787
    304 rdf:type schema:CreativeWork
    305 sg:pub.10.1038/nri888 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004545980
    306 https://doi.org/10.1038/nri888
    307 rdf:type schema:CreativeWork
    308 sg:pub.10.1038/nrm3479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022835250
    309 https://doi.org/10.1038/nrm3479
    310 rdf:type schema:CreativeWork
    311 sg:pub.10.1038/onc.2013.458 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021782376
    312 https://doi.org/10.1038/onc.2013.458
    313 rdf:type schema:CreativeWork
    314 grid-institutes:None schema:alternateName Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800, Villejuif, France
    315 schema:name Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800, Villejuif, France
    316 Gustave Roussy Cancer Campus, F-94800, Villejuif, France
    317 INSERM, U1015, F-94800, Villejuif, France
    318 Université Paris Sud/Paris XI, Faculté de Médecine, F-94270, Le Kremlin Bicêtre, France
    319 rdf:type schema:Organization
    320 grid-institutes:grid.1003.2 schema:alternateName School of Medicine, University of Queensland, 4006, Herston, QLD, Australia
    321 schema:name Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, 4006, Herston, QLD, Australia
    322 School of Medicine, University of Queensland, 4006, Herston, QLD, Australia
    323 rdf:type schema:Organization
    324 grid-institutes:grid.14925.3b schema:alternateName Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800, Villejuif, France
    325 schema:name Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006, Paris, France
    326 INSERM, U1138, F-75006, Paris, France
    327 Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800, Villejuif, France
    328 Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006, Paris, France
    329 Université Pierre et Marie Curie/Paris VI, F-75006, Paris, France
    330 rdf:type schema:Organization
    331 grid-institutes:grid.414093.b schema:alternateName Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015, Paris, France
    332 schema:name Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006, Paris, France
    333 INSERM, U1138, F-75006, Paris, France
    334 Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800, Villejuif, France
    335 Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015, Paris, France
    336 Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006, Paris, France
    337 Université Pierre et Marie Curie/Paris VI, F-75006, Paris, France
    338 rdf:type schema:Organization
    339 grid-institutes:grid.462844.8 schema:alternateName Université Pierre et Marie Curie/Paris VI, F-75006, Paris, France
    340 schema:name Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006, Paris, France
    341 Gustave Roussy Cancer Campus, F-94800, Villejuif, France
    342 INSERM, U1138, F-75006, Paris, France
    343 Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006, Paris, France
    344 Université Pierre et Marie Curie/Paris VI, F-75006, Paris, France
    345 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...